Daniel Turner

Dan Turner is a prominent expert in genomics and molecular biology, currently serving as the Chief Scientific Officer at ENHANC3D GENOMICS since February 2024, focusing on 3-dimensional genomic architecture and disease biology. Prior to this role, Dan had a significant tenure at Oxford Nanopore Technologies from July 2010 to February 2024, progressing through various leadership positions including Senior Vice President and Director of Applications, driving initiatives in real-time electronic analysis of biological molecules. Dan's earlier career included impactful positions at the Wellcome Trust Sanger Institute, where responsibilities included managing a sequencing technology development team, and postdoctoral research roles at Weill Cornell Medical College and University of Manchester Institute of Science and Technology. Dan holds a BA (MA Oxon) in Biochemistry from the University of Oxford.